Pharsight

1. Onivyde patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP17169098A	2022-02-04	Generics [UK] Limited	Granted and Under Opposition
EP17169098A	2022-02-02	Teva Pharmaceutical Industries Ltd.	Granted and Under Opposition
EP17169098A	2022-02-01	Sandoz AG	Granted and Under Opposition
EP13731230A	2018-02-05	Teva Pharmaceutical Industries Ltd	Revoked
EP05745505A	2017-10-11	Teva Pharmaceuticals Inc.	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9782349	IPSEN INC	Liposomes useful for drug delivery	May, 2025 (1 year, 7 months from now)
US10722508	IPSEN INC	Liposomes useful for drug delivery	May, 2025 (1 year, 7 months from now)
US9724303	IPSEN INC	Liposomes useful for drug delivery	May, 2025 (1 year, 7 months from now)
US8992970	IPSEN INC	Liposomes useful for drug delivery	May, 2025 (1 year, 7 months from now)
US8329213	IPSEN INC	Liposomes useful for drug delivery	Jan, 2027 (3 years from now)
US8147867	IPSEN INC	Liposomes useful for drug delivery	Aug, 2028 (4 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730891	IPSEN INC	Liposomes useful for drug delivery	May, 2025 (1 year, 7 months from now)
US8703181	IPSEN INC	Liposomes useful for drug delivery	May, 2025 (1 year, 7 months from now)
US11369597	IPSEN INC	Methods for treating pancreatic cancer using combination therapies	Jun, 2033 (9 years from now)
US9717724	IPSEN INC	Methods for treating pancreatic cancer using combination therapies	Jun, 2033 (9 years from now)
US9492442	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (9 years from now)
US9364473	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (9 years from now)
US9339497	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (9 years from now)
US9452162	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (9 years from now)
US10980795	IPSEN INC	Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan	Jun, 2033 (9 years from now)
US10456360	IPSEN INC	Stabilizing camptothecin pharmaceutical compositions	Oct, 2036 (13 years from now)
US10993914	IPSEN INC	Stabilizing camptothecin pharmaceutical compositions	Oct, 2036 (13 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Oct 22, 2022

Drugs and Companies using IRINOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2015

Treatment: Treatment of metastatic adenocarcinoma of the pancreas that has progressed on gemcitabine-based therapy, in combination with 5-fluorouracil and leucovorin; Treatment of pancreatic cancer; Treatment of...

Dosage: INJECTABLE, LIPOSOMAL;INTRAVENOUS